间充质干细胞治疗糖尿病的研究进展

糖尿病是目前困扰人类健康的第三大杀手。胰岛移植作为糖尿病的一种有效方法早已得到公认,但是胰岛供体的缺乏和移植排斥反应的存在限制了胰岛移植的临床应用1]。胰岛素替代疗法是目前治疗糖尿病最有效的方法。然而这种方法也有许多缺陷。间充质干细胞(mesenchymal stem cell,MSC)具有多向分化潜能的均质性细胞,具有供源丰富、易于获得、有自由供体、避免免疫排斥等优点,因而是较为理想的胰岛B细胞来源2]。近年来,众多实验研究表明了通过诱导MSC分化为胰岛B细胞治疗糖尿病的可能性。

Development of Mesenchymal Stem Cell in Treating Diabetes

Diabetes is now the third killer that threatens human health in the world.Islets transplantation has been widely accepted as an effective way for diabetes treatment.But transplantation rejection and shortage of cadaver pancreases limit its use in the clinic.Insulin replacement therapy is the widely-used method for diabetes treatment.However,there are many defects for this treatment.Mesenchymal stem cell(MSC) is a kind of cells with multipotent differentiation.It possesses the properties of abundant resources,convenient availability,free donor,and immune privilege etc,indicating that it is the ideal origin for pancreatic islet B type cells.In recent years,more and more studies have shown the possibility of the induction from MSCs into insulin-producing pancreatic islet B type cells.